Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 617 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Leading Change in Cancer Clinical Research, Because Our Patients Can’t Wait May 31, 2024 When Ovarian Cancer Returns, Surgery May Be a Good Choice for... January 12, 2022 6 Things That Helped Me Think Positively During Cancer: A Patient... August 16, 2022 Cholesterol Drug May Help Protect the Heart during Chemotherapy for Lymphoma September 8, 2023 Load more HOT NEWS Hormone Therapy Has A Stronger Impact On A Woman’s Quality Of... Announcing ‘Cancer Revolution’ – a world-first exhibition to engage people with... Final OS and the Exploratory Analysis of the Outcome with Osimertinib... How People With Advanced Cancer Can Find Meaning Toward the End...
